Saturday’s Midday Movers: Zogenix (ZGNX), 3D Systems (DDD), Glu Mobile (GLUU), Clovis Oncology (CLVS), Novavax (NVAX)

So far Saturday, February 8, NASDAQ is down -1.35% and the S&P is down -0.62%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Zogenix (ZGNXResearch Report), 3D Systems (DDDResearch Report), Glu Mobile (GLUUResearch Report), Clovis Oncology (CLVSResearch Report) and Novavax (NVAXResearch Report).

Zogenix is down -15.92% in midday trading to $32.12. Shares opened today at $38.20. The company has a 52-week low of $32.01 and a 52-week high of $57.22. On the Street’s front, the average 12-month analyst price target for the stock is $56.75, marking a 48.56% potential upside from current levels. In a report released yesterday, Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on ZGNX, with a price target of $67.00, which represents a potential upside of 75% from where the stock is currently trading. Separately, on the same day, Ladenburg Thalmann’s Michael Higgins downgraded the stock to Hold and has a price target of $35.00.

3D Systems is down -9% in midday trading to $10.92. Shares opened today at $12.00. The company has a 52-week low of $6.47 and a 52-week high of $14.50. On the Street’s front, the average 12-month analyst price target for the stock is $11.67, marking a -2.75% potential downside from current levels. In a report issued on January 28, Piper Sandler analyst Troy Jensen downgraded DDD to Hold, with a price target of $12.00, which represents a slight downside potential from current levels. Separately, on January 16, Loop Capital Markets’ Ananda Baruah downgraded the stock to Sell and has a price target of $9.00.

Glu Mobile is down -8.27% in midday trading to $7.32. Shares opened today at $7.98. The company has a 52-week low of $4.11 and a 52-week high of $11.75. On the Street’s front, the average 12-month analyst price target for the stock is $7.79, marking a -2.38% potential downside from current levels. In a report issued on February 6, Stifel Nicolaus analyst Drew Crum reiterated a Buy rating on GLUU, with a price target of $8.00, which represents a slight upside potential from current levels. In the last 30 days, insiders purchased $280.2K worth of GLUU shares. Over the last 3 months, the insider sentiment on Glu Mobile has been positive based on 41 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Clovis Oncology is down -7.92% in midday trading to $9.30. Shares opened today at $10.10. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $15.50, marking a 53.47% potential upside from current levels. In a report issued on January 31, H.C. Wainwright analyst Edward White maintained a Buy rating on CLVS, with a price target of $27.00, which implies an upside of 167% from current levels. Separately, on January 23, Merrill Lynch’s Tazeen Ahmad maintained a Hold rating on the stock and has a price target of $10.00. In the last 30 days, insiders purchased $299.8K worth of CLVS shares.

Novavax is down -6.66% in midday trading to $6.31. Shares opened today at $6.76. The company has a 52-week low of $3.54 and a 52-week high of $46.60. On the Street’s front, the average 12-month analyst price target for the stock is $17.38, marking a 157.10% potential upside from current levels. In a report issued on January 27, Ladenburg Thalmann analyst Michael Higgins maintained a Buy rating on NVAX, with a price target of $27.50, which implies an upside of 307% from current levels. Over the last 3 months, the insider sentiment on Novavax has been negative based on 10 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>